Alpa Labs Profit Plunges 80% YoY on Drastic Other Income Collapse

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Alpa Labs Profit Plunges 80% YoY on Drastic Other Income Collapse
Overview

Alpa Laboratories Ltd. reported a severe drop in profitability for the quarter ended December 31, 2025. Despite a 13.46% YoY revenue increase to ₹2,967.12 lacs (standalone), PAT plummeted by 80.67% YoY to ₹171.89 lacs. This sharp decline was primarily driven by a drastic 97% YoY fall in 'Other Income' to ₹26.05 lacs. Consequently, consolidated PAT also fell 80.38% to ₹174.70 lacs, with EPS dropping to ₹0.89 (standalone) and ₹0.90 (consolidated). The nine-month standalone and consolidated PAT were down over 42% YoY.

📉 Alpa Laboratories Q3 FY26: Profitability Devastated by 'Other Income' Collapse

Alpa Laboratories Ltd. has unveiled its un-audited financial results for the third quarter of FY26, painting a grim picture of profitability despite modest revenue growth. The company reported a staggering 80.67% year-on-year (YoY) decline in standalone Profit After Tax (PAT), which fell to ₹171.89 lacs for the quarter ended December 31, 2025, from ₹889.30 lacs in the prior year period. Consolidated PAT fared similarly, dropping 80.38% YoY to ₹174.70 lacs.

The Income Statement Anomaly

The core reason behind this profitability devastation lies in a dramatic contraction of 'Other Income'. Standalone 'Other Income' plummeted by approximately 97% YoY to just ₹26.05 lacs from ₹880.17 lacs. Consolidated 'Other Income' saw a still-significant 89.65% YoY decrease to ₹91.10 lacs. This substantial non-operational income source, which had propped up profitability in prior periods, has largely evaporated, exposing the underlying operational performance.

While revenue from operations showed growth – 13.46% YoY standalone to ₹2,967.12 lacs and 11.07% YoY consolidated to ₹2,904.58 lacs – the sharp fall in 'Other Income' led to a 14.36% YoY decline in total standalone income to ₹2,993.17 lacs. Coupled with an 8.26% YoY increase in total expenses to ₹2,821.27 lacs, the result was a severe compression in margins and profitability.

Earnings Per Share (EPS) Tumbles

The consequence for shareholders is a drastic reduction in earnings. Standalone basic and diluted EPS fell to ₹0.89 from ₹4.24 YoY, a drop of over 79%. Consolidated EPS similarly declined to ₹0.90 from ₹4.23 YoY.

Nine-Month Performance Reflects Downtrend

The performance over the first nine months of FY26 also indicates a considerable profitability decline. Standalone PAT for the nine months stood at ₹1,359.61 lacs, down 42.79% YoY, with EPS at ₹6.54. Consolidated PAT for the period was ₹1,362.72 lacs, down 42.69% YoY, and EPS was ₹6.55.

Risks & Outlook: A Cloud of Uncertainty

Crucially, the provided filing contains no management guidance, outlook, or commentary. This absence, coupled with the reliance on 'Other Income' for prior period profitability, presents a significant risk. Investors are left without clarity on the sustainability of core operations or future growth drivers. The results are also un-audited and subject to a limited review, adding another layer of caution. The company operates in a single segment: Drugs & Chemicals.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.